# Indaptus Therapeutics, Inc.: financial statements, quarterly

INDP · Nasdaq · CIK 1857044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/indp.md) · [Financials](/companies/indp/financials.md) · [Filings](/companies/indp/filings.md) · [Insiders](/companies/indp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/indp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [2,227](/filings/0001493152-24-044537.md) | [2,035 d](/filings/0001493152-25-010136.md) | [1,591](/filings/0001641172-25-010099.md) | [1,714](/filings/0001641172-25-023333.md) | [1,466](/filings/0001493152-25-021759.md) | [2,480 d](/filings/0001493152-26-010585.md) | [2,811](/filings/0001493152-26-023362.md) | [2,167](/filings/0001493152-26-037579.md) | [1,518](/filings/0001493152-25-021759.md) | [2,845 d](/filings/0001493152-26-010585.md) | [491](/filings/0001493152-26-023362.md) | [363](/filings/0001493152-26-037579.md) |
| Operating income | $k | [(4,248)](/filings/0001493152-24-044537.md) | [(4,180) d](/filings/0001493152-25-010136.md) | [(3,943)](/filings/0001641172-25-010099.md) | [(4,109)](/filings/0001641172-25-023333.md) | [(3,142)](/filings/0001493152-25-021759.md) | [(4,172) d](/filings/0001493152-26-010585.md) | [(4,573)](/filings/0001493152-26-023362.md) | [(4,457)](/filings/0001493152-26-037579.md) | [(2,648)](/filings/0001493152-25-021759.md) | [(8,156) d](/filings/0001493152-26-010585.md) | [(2,160)](/filings/0001493152-26-023362.md) | [(1,809)](/filings/0001493152-26-037579.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,922)](/filings/0001493152-24-044537.md) | [(4,003) d](/filings/0001493152-25-010136.md) | [(3,807)](/filings/0001493152-25-021759.md) | [(4,015)](/filings/0001493152-25-021759.md) | [(3,069)](/filings/0001493152-25-021759.md) | [(4,131) d](/filings/0001493152-26-010585.md) | [(4,532)](/filings/0001493152-26-037579.md) | [(5,229)](/filings/0001493152-26-037579.md) | [(2,975)](/filings/0001493152-25-021759.md) | [(8,112) d](/filings/0001493152-26-010585.md) | [(2,541)](/filings/0001493152-26-037579.md) | [(1,795)](/filings/0001493152-26-037579.md) |
| Diluted EPS | $ per share | [(0.47)](/filings/0001493152-24-044537.md) | not reported | [(0.45)](/filings/0001641172-25-010099.md) | [(13.16)](/filings/0001641172-25-023333.md) | [(9.04)](/filings/0001493152-25-021759.md) | not reported | [(9.11)](/filings/0001493152-26-023362.md) | [(9.09)](/filings/0001493152-26-037579.md) | [(2.98)](/filings/0001493152-25-021759.md) | not reported | [(0.23)](/filings/0001493152-26-023362.md) | [(0.02)](/filings/0001493152-26-037579.md) |
| Basic EPS | $ per share | [(0.47)](/filings/0001493152-24-044537.md) | not reported | [(0.45)](/filings/0001641172-25-010099.md) | [(13.16)](/filings/0001641172-25-023333.md) | [(9.04)](/filings/0001493152-25-021759.md) | not reported | [(9.11)](/filings/0001493152-26-023362.md) | [(9.09)](/filings/0001493152-26-037579.md) | [(2.98)](/filings/0001493152-25-021759.md) | not reported | [(0.23)](/filings/0001493152-26-023362.md) | [(0.02)](/filings/0001493152-26-037579.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.0](/filings/0001493152-23-039523.md) | [13.4](/filings/0001493152-25-010136.md) | [9.7](/filings/0001493152-24-018162.md) | [7.3](/filings/0001493152-24-031158.md) | [7.4](/filings/0001493152-24-044537.md) | [5.8](/filings/0001493152-26-010585.md) | [3.9](/filings/0001641172-25-010099.md) | [6.2](/filings/0001641172-25-023333.md) | [5.8](/filings/0001493152-25-021759.md) | [8.5](/filings/0001493152-26-037579.md) | [1.5](/filings/0001493152-26-023362.md) | [7.6](/filings/0001493152-26-037579.md) |
| Current assets | $m | [16.8](/filings/0001493152-23-039523.md) | [14.0](/filings/0001493152-25-010136.md) | [10.3](/filings/0001493152-24-018162.md) | [7.5](/filings/0001493152-24-031158.md) | [7.6](/filings/0001493152-24-044537.md) | [6.6](/filings/0001493152-26-010585.md) | [5.0](/filings/0001641172-25-010099.md) | [6.4](/filings/0001641172-25-023333.md) | [6.4](/filings/0001493152-25-021759.md) | [9.3](/filings/0001493152-26-023362.md) | [2.2](/filings/0001493152-26-023362.md) | not reported |
| Total assets | $m | [17.8](/filings/0001493152-23-039523.md) | [14.9](/filings/0001493152-25-010136.md) | [10.9](/filings/0001493152-24-018162.md) | [8.1](/filings/0001493152-24-031158.md) | [8.2](/filings/0001493152-24-044537.md) | [7.3](/filings/0001493152-26-010585.md) | [5.4](/filings/0001641172-25-010099.md) | [6.8](/filings/0001641172-25-023333.md) | [6.8](/filings/0001493152-25-021759.md) | [9.3](/filings/0001493152-26-037579.md) | not reported | [12.0](/filings/0001493152-26-037579.md) |
| Current liabilities | $m | [2.4](/filings/0001493152-23-039523.md) | [2.8](/filings/0001493152-25-010136.md) | [1.5](/filings/0001493152-24-018162.md) | [1.9](/filings/0001493152-24-031158.md) | [2.2](/filings/0001493152-24-044537.md) | [3.4](/filings/0001493152-26-010585.md) | [2.6](/filings/0001641172-25-010099.md) | [8.5](/filings/0001641172-25-023333.md) | [2.2](/filings/0001493152-25-021759.md) | [6.2](/filings/0001493152-26-023362.md) | [0.9](/filings/0001493152-26-023362.md) | not reported |
| Total liabilities | $m | [2.5](/filings/0001493152-23-039523.md) | [2.8](/filings/0001493152-25-010136.md) | [1.6](/filings/0001493152-24-018162.md) | [2.0](/filings/0001493152-24-031158.md) | [2.2](/filings/0001493152-24-044537.md) | [3.4](/filings/0001493152-25-010136.md) | not reported | not reported | not reported | [6.2](/filings/0001493152-26-037579.md) | not reported | [0.6](/filings/0001493152-26-037579.md) |
| Shareholders' equity | $m | [15.3](/filings/0001493152-24-044537.md) | [12.1](/filings/0001493152-26-010585.md) | [9.4](/filings/0001493152-25-021759.md) | [6.2](/filings/0001493152-25-021759.md) | [6.0](/filings/0001493152-25-021759.md) | [3.9](/filings/0001493152-26-037579.md) | [2.8](/filings/0001493152-26-037579.md) | [(1.7)](/filings/0001493152-26-037579.md) | [4.6](/filings/0001493152-25-021759.md) | [3.2](/filings/0001493152-26-037579.md) | [1.2](/filings/0001493152-26-037579.md) | [11.4](/filings/0001493152-26-037579.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,734) d](/filings/0001493152-24-044537.md) | [(2,602) d](/filings/0001493152-25-010136.md) | [(3,936)](/filings/0001641172-25-010099.md) | [(2,478) d](/filings/0001641172-25-023333.md) | [(2,513) d](/filings/0001493152-25-021759.md) | [(3,396) d](/filings/0001493152-26-010585.md) | [(5,047)](/filings/0001493152-26-023362.md) | [(4,018) d](/filings/0001493152-26-037579.md) | [(2,567) d](/filings/0001493152-25-021759.md) | [(3,191) d](/filings/0001493152-26-010585.md) | [(7,010)](/filings/0001493152-26-023362.md) | [(1,928) d](/filings/0001493152-26-037579.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.3](/filings/0001493152-23-039523.md) | [8.4](/filings/0001493152-24-018162.md) | [8.4](/filings/0001493152-24-031158.md) | [8.4](/filings/0001493152-24-044537.md) | [8.4](/filings/0001641172-25-010099.md) | [0.3](/filings/0001641172-25-023333.md) | [0.3](/filings/0001493152-25-021759.md) | [0.5](/filings/0001493152-26-023362.md) | [0.6](/filings/0001493152-26-037579.md) | [1.0](/filings/0001493152-25-021759.md) | [11.0](/filings/0001493152-26-023362.md) | [116](/filings/0001493152-26-037579.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 133,242,324 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037579.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.